Back to Search Start Over

EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes

Authors :
Nancy Law
Cathy Logan
Randy Taplitz
Source :
Viruses, Vol 16, Iss 8, p 1294 (2024)
Publication Year :
2024
Publisher :
MDPI AG, 2024.

Abstract

The acquisition or reactivation of Epstein–Barr virus (EBV) after allogeneic Hematopoietic Stem Cell Transplant (HSCT) can be associated with complications including the development of post-transplant lymphoproliferative disorder (PTLD), which is associated with significant morbidity and mortality. A number of risk factors for PTLD have been defined, including T-cell depletion, and approaches to monitoring EBV, especially in high-risk patients, with the use of preemptive therapy upon viral activation have been described. Newer therapies for the preemption or treatment of PTLD, such as EBV-specific cytotoxic T-cells, hold promise. Further studies to help define risks, diagnosis, and treatment of EBV-related complications are needed in this at-risk population.

Details

Language :
English
ISSN :
19994915
Volume :
16
Issue :
8
Database :
Directory of Open Access Journals
Journal :
Viruses
Publication Type :
Academic Journal
Accession number :
edsdoj.0d963fd3f1464553a23a8d1b541e7711
Document Type :
article
Full Text :
https://doi.org/10.3390/v16081294